Hospital medicines list news 3
Prescribing from 1 July 2013 - information for hospitals and health professionals
11 June 2013
DHB hospitals will start prescribing from a nationally consistent pharmaceutical list from 1 July 2013. The Hospital Medicines List (HML) – Part II of Section H of the Pharmaceutical Schedule - has been developed by clinicians and PHARMAC over the past two-and-a half years. It will mean New Zealanders get access to the same hospital medicine, whatever part of the country they are being treated.
In this issue:
A PDF version of the new 1 July 2013 Hospital Medicines List (HML) will be added to our website later this week. Keep an eye on the HML home page. This means you’ll be able to view the first edition of the HML printed book that DHBs will start receiving after 24 June.
The PDF and HML book include some changes to restrictions, and new products have been added since the notification of the final lists in May. These details have been changed following DHB feedback on the lists. The HML, like the Pharmaceutical Schedule, will be updated monthly with changes. The first HML Update will be sent to DHBs along with the printed book.
We are working to have a more interactive HML search facility as soon as possible after 1 July. The interactive HML will combine the PDF and the Update information.
Last issue we told you some HML medicines have prescriber-type or indication restrictions. This includes some anti-infectives which may be prescribed from outside the required prescriber-groups. When there is a hospital protocol in place to use a pharmaceutical for an indication is an example of when this can happen. (See our website for further information on prescriber options.)
To assist hospitals in developing protocols where they don’t already exist, DHBs with current protocols have generously been working with PHARMAC to share their examples. This information sharing is appreciated and being managed through DHB’s Chief Pharmacists/pharmacy departments.
We are happy to help facilitate protocol sharing for other clinical groups. If this would be of value to you or your colleagues, please get in touch.
In the next few weeks PHARMAC staff will be talking at meetings in a number of DHBs:
- 12 June, 8:15am – Hutt DHB – Advanced Medical Meeting
- 17 June, 1pm – Middlemore Hospital – Clinical Directors
- 18 June, 12:00pm – Timaru Hospital – Continuing Medical Education meeting
- 20 June, 12.15pm – Middlemore Hospital – Grand Round
- 21 June, 12:30pm – Greymouth Base Hospital – The introduction of the Hospital Medicines List from the 1st of July 2013 - what does it mean for you and your patients?
- 24 June – Capital Coast Health – Clinical Leaders
- 9 July – Wairarapa – The Introduction of the Hospital Medicines List from 1 July 2013 - an overview for clinicians
If you are at any of these DHBs and have not been invited to the meeting, we can put you in touch with the local organisers. Contact us on the email and phone numbers at the end of this newsletter.
We will continue to visit and talk with DHB staff where possible once the transition phase starts in July, as part of responding to feedback and monitoring how things are working on the ground.
We are finalising our processes for Named Patient Pharmaceutical Assessment (NPPA) applications for DHB clinicians wanting to request exceptions to the HML. Some NPPA applications will require ‘Rapid Assessment’ and there will be a new application form for DHBs available from 1 July (if not sooner) for decisions about treatment required in less than five days.
DHBs will be able to use local decision making processes to allow rapid exceptions. If a DHB prefers, it may use the PHARMAC rapid process and complete the PHARMAC form from the website. PHARMAC will assess the application as quickly as possible.
An overview flowchart of the options for requesting an exception (whether through your DHB or PHARMAC) is being provided on our website shortly. This will include information about where approved pharmaceutical applications are funded from.
Copies of this flowchart will be sent to DHBs along with the hard copies of the HML later in June. The full NPPA policy is also available online.
The specialist groups the HML prescriber-type restriction ‘internal medicine’ refers to are those covered by the Medical Council’s definition(external link). This is wider than the definition in at least some hospitals where internal medicine often means general physician only.
For example, isoniazid has a prescriber-type restriction ‘internal medicine physician’. This means that respiratory physicians are included in the prescriber group.
If you have a question, comment or concern please email HML@pharmac.govt.nz, phone 0800 66 00 50 or fax 64 4 974 7819.
Last updated: 2 November 2015